As stock-moving events go for biotechs, getting the EU to sign off on the manufacturing facility doesn't rank very high. Honestly, I can't even remember seeing a biotech ever issuing a press release about it.
Yet Alexza Pharmaceuticals
So what's the big deal? While an approval is the real stock-moving event, clearing up manufacturing issues seem to be the key to getting Adasuve on the market.
In May, the Food and Drug Administration rejected the drug, and management said manufacturing issues were the only major problem the agency had with Adasuve. Alexza already resubmitted for approval and expects a new ruling by the FDA on or before Dec. 21.
If one regulatory body has signed off on the manufacturing of the drug, it's certainly a good sign that the FDA will do the same. Just keep in mind that the agencies don't always move in lockstep. There are plenty of examples of drugs that are approved in the E.U. and not in the U.S.: Merck's
Generally speaking, it's easier to get a drug approved in the EU than the U.S., but the stateside market is more important to Alexza because it has the full rights to the drug here but licensed out the European rights to Grupo Ferrer.
Unfortunately, manufacturing remains mostly a black box to investors. The EU manufacturing approval shines a little light on the box, but investors won't be certain that there isn't anything else hiding in the box until the FDA rules at the end of the year. Expect a much bigger jump than the one we saw today if the FDA approves the drug this time around.
The biggest binary event, the presidential election, is around the corner. Check out the Fool's new free report, "These Stocks Could Skyrocket After the 2012 Presidential Election," where you'll get ideas for companies that can benefit from each candidate's platform. Get your free copy.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.